Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - formoterol fumarate dihydrate, quantity: 9 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - long-term treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise induced asthma) in adults and children aged 12 years and over and who are receiving inhaled or oral corticosteroids and who require bronchodilator therapy.,oxis turbuhaler can be used on demand (prn) in asthmatics over the age of 18 years who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed alone by occasional use of short acting inhaled beta-2 agonists.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - formoterol fumarate, quantity: 12 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - for long-term, regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercised-induced asthma) in patients aged 5 years or more who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta-2 agonists. indications as at 27 march 2001: for the long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in patients aged 5 years or more who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta-2 agonists. for the prophylaxis and treatment of bronchoconstriction in patients with reversible or irreversible chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 100 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty 10 microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; hydrochloric acid - copd trimbow 100/6/10 is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid (ics) and a long-acting beta2-agonist (laba) or a combination of a laba and a long-acting muscarinic antagonist (lama). asthma trimbow 100/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Kenya - English - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki vihar road, andheri (east) - - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Kenya - English - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki-vihar road, andheri (east), - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Israel - English - Ministry of Health

novartis israel ltd - formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 12 mcg - formoterol - formoterol - foradil is indicated in asthma ( including nocturnal asthma and exercise-induced symptoms) in those treated with inhaled corticosteroids who also require a long-acting beta agonist in accordance with current treatment guidelines.prophylaxis and treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and emphysema.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orient europharma (m) sdn bhd - beclomethasone dipropionate; formoterol fumarate dihydrate; glycopyrronium bromide -

Israel - English - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.copd :symptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - formoterol fumatrate dihydrate - powder for inhalation - 12 mcg/dose - formoterol